The Week in Review: Huapont Pharma Raises $146 Million
Chongqing Huapont Pharma plans to raise $146 million in a private placement to fund four capital projects; Lee's Pharmaceutical signed a term sheet with RegeneRx to in-license the China rights for three Thymosin Beta 4-based molecules; GlaxoSmithKline and Hanmi Pharma agreed to co-develop and co-market drugs in Korea and China; Hubei Minkang Pharma signed a MoU to acquire a 30% to 51% interest in Hubei Merryclin Pharma; Bayer HealthCare extended its research partnership with Beijing’s Tsinghua University for another three years; GE Healthcare will seek to increase its China revenues by expanding into rural markets with new products; Roche will “significantly” reduce the price the company charges in India for two expensive biotech cancer drugs; and Novasep opened a new 21,400 square foot facility in Shanghai’s Pudong district. More details…. Stock Symbols: (SHE: 002004) (OTCBB: RGRX) (NYSE: GSK) (OTCBB: HBMK) (Xetra: BAY) (NYSE: GE) (VX: ROG) Share this with colleagues: // //  
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here